Document is current
Any future updates will be listed below
-
Authors
Lukkarinen, Heikki https://orcid.org/0000-0002-8162-6982
Jeppsson, Anna
Wikkelsö, Carsten
Blennow, Kaj
Zetterberg, Henrik
Constantinescu, Radu
Remes, Anne M.
Herukka, Sanna-Kaisa
Hiltunen, Mikko
Rauramaa, Tuomas
Nägga, Katarina
Leinonen, Ville
Tullberg, Mats
-
Funding
Funding for this research was provided by:
Kuopion Yliopistollinen Sairaala (5252614)
Academy of Finland (339767)
Sigrid Juséliuksen Säätiö
- License Information
-
More Information
Article History
Received: 16 October 2021
Accepted: 20 January 2022
First Online: 5 February 2022
Declarations
:
: The study was approved by the regional ethics committee in Kuopio/Finland and Gothenburg/Sweden. Written informed consent was signed by all included participants. The implementation and governance of this study was performed in agreement with the Declaration of Helsinki.
: Not applicable.
: HZ has served at scientific advisory boards and/or as a consultant for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, CogRx and Red Abbey Labs, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. CW and MT have received support from Codman/Integra for lecturing.
